Gross, Jasmin;
Palmowski, Karin;
Doleschel, Dennis;
Rix, Anne;
Gremse, Felix;
Verburg, Frederic;
Mottaghy, Felix M.;
Kiessling, Fabian;
Lederle, Wiltrud;
Palmowski, Moritz
Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and 18F-FDG-PET/CT
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and 18F-FDG-PET/CT
Beteiligte:
Gross, Jasmin;
Palmowski, Karin;
Doleschel, Dennis;
Rix, Anne;
Gremse, Felix;
Verburg, Frederic;
Mottaghy, Felix M.;
Kiessling, Fabian;
Lederle, Wiltrud;
Palmowski, Moritz
Beschreibung:
<jats:p>Aim of the Study. To compare Annexin V-based optical apoptosis imaging with the assessment of the glucose metabolism using 18F-FDG-PET/CT for monitoring the response to cytotoxic (carboplatin) and anti-angiogenic (sunitinib) therapy. Methods. For apoptosis imaging, the near-infrared probe Annexin Vivo750 was used in combination with fluorescence molecular tomography and microcomputed tomography (FMT/µCT). Glucose metabolism was assessed using 18F-FDG-PET/CT. Five groups of nude mice bearing lung cancer xenografts (A549) were investigated: (i) untreated controls and two groups after (ii) cytotoxic (carboplatin) or (iii) anti-angiogenic (sunitinib) treatment for four and nine days, respectively. Imaging data were validated by immunohistochemistry. Results. In response to carboplatin treatment, an inverse relation was found between the change in glucose metabolism and apoptosis in A549 tumors. Annexin Vivo showed a continually increasing tumor accumulation, while the tumor-to-muscle ratio of 18F-FDG continuously decreased during therapy. Immunohistochemistry revealed a significantly higher tumor apoptosis (<jats:inline-formula>
<math xmlns="http://www.w3.org/1998/Math/MathML" id="M1">
<mi>p</mi>
<mo>=</mo>
<mn>0.007</mn>
</math>
</jats:inline-formula>) and a minor but not significant reduction in vessel density only at day 9 of carboplatin therapy. Interestingly, during anti-angiogenic treatment there was an early drop in the tumor-to-muscle ratio between days 0 and 4, followed by a subsequent minor decrease (18F-FDG tumor-to-muscle-ratio: 1.9 ± 0.4; day 4: 1.1 ± 0.2; day 9: 1.0 ± 0.2; <jats:inline-formula>
<math xmlns="http://www.w3.org/1998/Math/MathML" id="M2">
<mi>p</mi>
<mo>=</mo>
<mn>0.021</mn>
</math>
</jats:inline-formula> and <jats:inline-formula>
<math xmlns="http://www.w3.org/1998/Math/MathML" id="M3">
<mi>p</mi>
<mo>=</mo>
<mn>0.001</mn>
</math>
</jats:inline-formula>, respectively). The accumulation of Annexin Vivo continuously increased over time (Annexin Vivo: untreated: 53.7 ± 36.4 nM; day 4: 87.2 ± 53.4 nM; day 9: 115.1 ± 103.7 nM) but failed to display the very prominent early induction of tumor apoptosis that was found by histology already at day 4 (TUNEL: <jats:inline-formula>
<math xmlns="http://www.w3.org/1998/Math/MathML" id="M4">
<mi>p</mi>
<mo>=</mo>
<mn>0.0036</mn>
</math>
</jats:inline-formula>) together with a decline in vessel density (CD31: <jats:inline-formula>
<math xmlns="http://www.w3.org/1998/Math/MathML" id="M5">
<mi>p</mi>
<mo>=</mo>
<mn>0.004</mn>
</math>
</jats:inline-formula>), followed by no significant changes thereafter. Conclusion. Both molecular imaging approaches enable visualizing the effects of cytotoxic and anti-angiogenic therapy in A549 tumors. However, the early and strong tumor apoptosis induced by the anti-angiogenic agent sunitinib was more sensitively and reliably captured by monitoring of the glucose metabolism as compared to Annexin V-based apoptosis imaging.</jats:p>